Losartan decreases p42/44 MAPK signaling and preserves LZ+ MYPT1 expression

PLoS ONE

Volumn 4, Issue 4, 2009, Pages

  Ararat, Erhan ^a   Brozovich, Frank V ^a  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; LEUCINE ZIPPER PROTEIN; LOSARTAN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE 3; MYOSIN LIGHT CHAIN PHOSPHATASE; PROTEIN MYPT1; UNCLASSIFIED DRUG; ANGIOTENSIN RECEPTOR ANTAGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ISOENZYME; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHOPROTEIN PHOSPHATASE 1; PPP1R12A PROTEIN, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA MEDIA; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; ENZYME ACTIVATION; ENZYME INHIBITION; HEART FAILURE; HEART INFARCTION; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RAT; SIGNAL TRANSDUCTION; VASODILATATION; ANIMAL; AORTA; CYTOLOGY; GENETICS; HEART LEFT VENTRICLE FUNCTION; HISTOLOGY; HUMAN; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; VASCULAR SMOOTH MUSCLE;

RATTUS;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; AORTA; CAPTOPRIL; ENZYME ACTIVATION; HEART FAILURE; HUMANS; ISOENZYMES; LOSARTAN; MALE; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MUSCLE, SMOOTH, VASCULAR; MYOCARDIAL INFARCTION; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN PHOSPHATASE 1; RATS; RATS, SPRAGUE-DAWLEY; VENTRICULAR FUNCTION, LEFT;

EID: 65249154257     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0005144     Document Type: Article

References (48)

1. Gong MC, Cohen P, Kitazawa T, Ikebe M, Masuo M, et al. (1992) Myosin light chain phosphatase activities and the effects of phosphatase inhibitors in tonic and phasic smooth muscle. J Biol Chem 267: 14662-14668.
2. Ogut O, Brozovich FV (2000) Determinants of the contractile properties in the embryonic chicken gizzard and aorta. Am J Physiol 279: C1722-C1732.
3. Hartshorne DJ (1987) Biochemistry of the Contractile Process in Smooth Muscle. Physiology of the Gastrointestinal Tract. New York, New York: Raven Press. pp 432-482.
4. Hartshorne DJ, Ito M, Erdîdi F (1998) Myosin light chain phosphatase: subunit composition, interactions and regulation. J Muscle Res Cell Motil 19: 325-341.
5. Shimizu H, Ito M, Miyahara M, Ichikawa K, Okubo S, et al. (1994) Characterization of the myosin-binding subunit of smooth muscle myosin phosphatase. J Biol Chem 269: 30407-30411.
6. Khatri JJ, Joyce KM, Brozovich FV, Fisher SA (2001) Role of myosin phosphatase isoforms in cGMP-mediated smooth muscle relaxation. J Biol Chem 276: 37250-37257.
7. Furchgott RF (1999) Endothelium-derived relaxing factor: Discovery, early studies, and identification as nitric oxide. Biosci Rep 19: 235-251.
8. Furchgott RF, Zawadzki JV (1980) The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288: 373-376.
9. Alioua A, Tanaka Y, Wallner M, Hofmann F, Ruth P, et al. (1998) The large conductance, voltage-dependent, and calcium-sensitive K+ channel, Hslo, is a target of cGMP-dependent protein kinase phosphorylation in vivo. J Biol Chem 273: 32950-32956.
10. Schmidt HH, Lohmann SM, Walter U (1993) The nitric oxide and cGMP signal transduction system: regulation and mechanism of action. Biochem Biophys Acta 1178: 153-175.
11. Fukao M, Mason HS, Britton FC, Kenyon JL, Horowitz B, et al. (1999) Cyclic GMP-dependent protein kinase activates cloned BKCa channels expressed in mammalian cells by direct phosphorylation at serine 1072. J Biol Chem 274: 10927-10935.
12. Surks HK, Mochizuki N, Kasai Y, Georgescu SP, Tang KM, et al. (1999) Regulation of myosin phosphatase by a specific interaction with cGMP-dependent protein kinase Ia. Science 286: 1583-1587.
13. Wu X, Haystead TA, Nakamoto RK, Somlyo AV, Somlyo AP (1998) Acceleration of myosin light chain dephosphorylation and relaxation of smooth muscle by telokin. Synergism with cyclic nucleotide-activated kinase. J Biol Chem 273: 11362-11369.
14. Walker LA, Macdonald JA, Liu XP, Nakamoto RK, Haystead TAJ, et al. (2001) Site-specific phosphorylation and point mutations of telokin modulate its Ca2+-desensitizing effect in smooth muscle. J Biol Chem 276: 24519-24524.
15. Khromov AS, Wang H, Choudhury N, McDuffie M, Herring BP, et al. (2006) Smooth muscle of telokin-deficient mice exhibits increased sensitivity to Ca2+ and decreased cGMP-induced relaxation. Proc Natl Acad Sci 103: 2440-2445.
16. Rembold CM, Foster DB, Strauss JD, Wingard CJ, Van Eyk JE (2000) cGMP-mediated phosphorylation of heat shock protein 20 may cause smooth muscle relaxation without myosin light chain dephosphorylation in swine carotid artery. J Physiol 524: 865-878.
17. Payne MC, Zhang HY, Shirasawa Y, Koga Y, Ikebe M, et al. (2004) Dynamic changes in expression of myosin phosphatase in a model of portal hypertension. Am J Physiol 286: H1801-1810.
18. Lu Y, Zhang H, Gokina N, Mandala M, Sato O, et al. (2008) Uterine artery myosin phosphatase isoform switching and increased sensitivity to SNP in a rat L-NAME model of hypertension of pregnancy. Am J Physiol 294: C564-571.
19. Zhang H, Fisher SA (2007) Conditioning effect of blood flow on resistance artery smooth muscle myosin phosphatase. Circ Res 100: 730-737.
20. Payne MC, Zhang HY, Prosdocimo T, Joyce KM, Koga Y, et al. (2006) Myosin phosphatase isoform switching in vascular smooth muscle development. J Mol Cell Cardiol 40: 274-282.
21. Huang QQ, Fisher SA, Brozovich FV (2004) Unzipping the role of myosin light chain phosphatase in smooth muscle cell relaxation. J Biol Chem 279: 597-603.
22. Chen FC, Ogut O, Rhee AY, Hoit BD, Brozovich FV (2006) Captopril prevents myosin light chain phosphatase isoform switching to preserve normal cGMP-mediated vasodilatation. J Mol Cell Cardiol 41: 488-495.
23. Chen FC, Brozovich FV (2008) Gene expression profiles of vascular smooth muscle show differential expression of mitogen-activated protein kinase pathways during captopril therapy of heart failure. J Vasc Res 45: 445-454.
24. Karim SM, Rhee AY, Given AM, Faulx MD, Hoit BD, et al. (2004) Vascular reactivity in heart failure. Role of myosin light chain phosphatase. Circ Res 95: 612-618.
25. Dirksen WP, Vladic F, Fisher SA (2000) A myosin phosphatase targeting subunit isoform transition defines a smooth muscle developmental phenotypic switch. Am J Physiol 278: C589-C600.
26. Pfeffer JM, Pfeffer MA, Braunwald E (1985) Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res 57: 84-95.
27. Pfeffer JM, Pfeffer MA, Braunwald E (1987) Hemodynamic benefits and prolonged survival with long-term captopril therapy in rats with myocardial infarction and heart failure. Circulation 75: I149-155.
28. Pourdjabbar A, Parker TG, Desjardins JF, Nguyen QT, Tsoporis JN, et al. (2005) Losartan and acute myocardial infarction in insulin-resistant Zucker fatty rats: Reduced ventricular arrhythmias and improved survival. Can J Physiol Pharmacol 83: 989-998.
29. Liu YH, Yang XP, Sharov VG, Nass O, Sabbah HN, et al. (1997) Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J Clin Invest 99: 1926-1935.
30. Richer C, Fornes P, Cazaubon C, Domergue V, Nisato D, et al. (1999) Effects of long-term angiotensin II AT1 receptor blockade on survival, hemodynamics and cardiac remodeling in chronic heart failure in rats. Cardiovasc Res 41: 100-108.
31. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, et al. (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327: 669-677.
32. Cohn JN, Tognoni G (2001) A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345: 1667-1675.
33. Pourdjabbar A, Parker TG, Nguyen QT, Desjardins JF, Lapointe N, et al. (2005) Effects of pre-, peri-, and postmyocardial infarction treatment with losartan in rats: effect of dose on survival, ventricular arrhythmias, function, and remodeling. Am J Physiol 288: H1997-2005.
34. Wooldridge AA, MacDonald JA, Erdodi F, Ma C, Borman MA, et al. (2004) Smooth muscle phosphatase is regulated in vivo by exclusion of phosphorylation of threonine 696 of MYPT1 by phosphorylation of Serine 695 in response to cyclic nucleotides. J Biol Chem 279: 34496-34504.
35. Nakamura K, Koga Y, Sakai H, Homma K, Ikebe M (2007) cGMP-dependent relaxation of smooth muscle is coupled with the change in the phosphorylation of myosin phosphatase. Circ Res 101: 712-722.
36. Somlyo AV (2007) Cyclic GMP regulation of myosin phosphatase: A new piece for the puzzle? Circ Res 101: 645-647.
37. Niiro N, Ikebe M (2001) Zipper-interacting protein kinase induces Ca2+-free smooth muscle contraction via myosin light chain phosphorylation. J Biol Chem 276: 29567-29574.
38. Somlyo AP, Somlyo AV (2003) Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol Rev 83: 1325-1358.
39. El-Toukhy A, Given AM, Ogut O, Brozovich FV (2006) PHI-1 interacts with the catalytic subunit of myosin light chain phosphatase to produce a Ca(2+) independent increase in MLC(20) phosphorylation and force in avian smooth muscle. FEBS Lett 580: 5779-5784.
40. Michael SK, Surks HK, Wang Y, Zhu Y, Blanton R, et al. (2008) High blood pressure arising from a defect in vascular function. Proc Natl Acad Sci 105: 6702-6707.
41. Abassi ZA, Gurbanov K, Mulroney SE, Potlog C, Opgenorth TJ, et al. (1997) Impaired nitric oxide-mediated renal vasodilation in rats with experimental heart failure: role of angiotensin II. Circulation 96: 3655-3664.
42. See F, Thomas W, Way K, Tzanidis A, Kompa A, et al. (2004) p38 mitogen-activated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the rat. J Am Coll Cardiol 44: 1679-1689.
43. Liang Q, Elson AC, Gerdes AM (2006) p38 MAP kinase activity is correlated with angiotensin II type 1 receptor blocker-induced left ventricular reverse remodeling in spontaneously hypertensive heart failure rats. J Card Fail 12: 479-486.
44. Mehta PK, Griendling KK (2007) Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol 292: C82-C97.
45. Weg-Remers S, Ponta H, Herrlich P, Konig H (2001) Regulation of alternative pre-mRNA splicing by the ERK MAP-kinase pathway. Embo J 20: 4194-4203.
46. Shukla S, Fisher SA (2008) Tra2beta as a novel mediator of vascular smooth muscle diversification. Circ Res 103: 485-492.
47. Hoit BD, Castro C, Bultron G, Knight S, Matlib MA (1999) Noninvasive evaluation of cardiac dysfunction by echocardiography in streptozotocin-induced diabetic rats. J Card Fail 5: 324-333.
48. Given AM, Ogut O, Brozovich FV (2007) MYPT1 mutants demonstrate the importance of aa 888-928 for the interaction with PKGI{alpha}. Am J Physiol 292: C432-439.